Citations

Clear

4847 citation(s) found for "Yu, Eric".

Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology
Schofield, Peter R. , Weiner, Michael W. , Xiong, Chengjie , Coble, Dean W. , Saito, Naomi , Aisen, Paul, Berman, Sarah , Cairns, Nigel J., Carrillo, María C. , Chui, Helena C., Chhatwal, Jasmeer P. , Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Goate, Alison , Gordon, Brian A. , Graff‐Radford, Neill R. , Day, Gregory S. , Hassenstab, Jason , Jack, Clifford R. , Jagust, William J. , Massoumzadeh, Parinaz , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Petersen, Ronald C. , Ringman, John M. , Salloway, Stephen , Saykin, Andrew J. , Shaw, Leslie M. , Trojanowski, John Q. , Vöglein, Jonathan , Weninger, Stacie, Bateman, Randall J. , Buckles, Virginia, Morris, John C. , Schofield, Peter R , Gordon, Brian A , Ikeuchi, T , Jack, Clifford R , Jagust, William J , Masters, Colin L , Vöglein, Jonathan , Saykin, Andrew J , Day, Gregory S , Bateman, Randall J , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Noble, James M , Xiong, Chengjie , Beckett, Laurel , Allegri, Ricardo , Benzinger, Tammie L.S. , Chui, Helena C. , Cruchaga, Carlos , Ghetti, Bernardino , Ikeuchi, Takeshi , Jucker, Mathias , Martins, Ralph N. , McDade, Eric , Toga, Arthur W.

Mayo Clinic

Brain | May 17, 2022 | Volume: 145 | Issue: 10 | Pages: 3594-3607

10.1093/brain/awac181 | PMID 35580594 Get It

AbstractThe extent to which the pathophysiology of autosomal dominant Alzheimer's disease corresponds to the pathophysiology of ‘sporadic’ late onset Alzheimer's disease is unknown, thus limiting the extrapolation of study findings and clinical trial results in autosomal dominant Alzheimer's disease to late onset Alzheimer's disease.We compared brain MRI and amyloid PET data, as well as CSF concentrations of amyloid-β42, amyloid-β40, tau and tau phosphorylated at position 181, in 292 carriers of pathogenic variants for Alzheimer's disease from the Dominantly Inherited Alzheimer Network, with corresponding data from 559 participants from the Alzheimer’s Disease Neuroimaging Initiative. Imaging data and CSF samples were reprocessed as appropriate to guarantee uniform pipelines and assays. Data analyses yielded rates of change before and after symptomatic onset of Alzheimer's disease, allowing the alignment of the ∼30-year age difference between the cohorts on a clinically meaningful anchor point, namely the participant age at symptomatic onset.Biomarker profiles were similar for both autosomal dominant Alzheimer's disease and late onset Alzheimer's disease. Both groups demonstrated accelerated rates of decline in cognitive performance and in regional brain volume loss after symptomatic onset. Although amyloid burden accumulation as determined by PET was greater after symptomatic onset in autosomal dominant Alzheimer's disease than in late onset Alzheimer's disease participants, CSF assays of amyloid-β42, amyloid-β40, tau and p-tau181 were largely overlapping in both groups. Rates of change in cognitive performance and hippocampal volume loss after symptomatic onset were more aggressive for autosomal dominant Alzheimer's disease participants.These findings suggest a similar pathophysiology of autosomal dominant Alzheimer's disease and late onset Alzheimer's disease, supporting a shared pathobiological construct.
Functional validation of a novel AAAS variant in an atypical presentation of Allgrove syndrome
Macke, Erica L. , Morales‐Rosado, Joel A. , Macklin‐Mantia, Sarah K. , Schmitz, Christopher T., Oskarsson, Björn , Klee, Eric W. , Wierenga, Klaas J. , Oskarsson, Björn , Schmitz, Christopher , Morales-Rosado, Joel A

Mayo Clinic

Molecular Genetics & Genomic Medicine | May 16, 2022 | Volume: 10 | Issue: 7 | Pages: No page available

10.1002/mgg3.1966 | PMID 35570467 Get It

AbstractBackgroundAchalasia‐addisonianism‐alacrima syndrome, frequently referred to as Allgrove syndrome or Triple A syndrome, is a multisystem disorder resulting from homozygous or compound heterozygous pathogenic variants in the gene encoding aladin (AAAS). Aladin is a member of the WD‐repeat family of proteins and is a component of the nuclear pore complex. It is thought to be involved in nuclear import and export of molecules. Here, we describe an individual with a paternally inherited truncating variant and a maternally inherited, novel missense variant in AAAS presenting with alacrima, achalasia, anejaculation, optic atrophy, muscle weakness, dysarthria, and autonomic dysfunction.MethodsWhole‐exome sequencing was performed in the proband, sister, and parents. Variants were confirmed by Sanger sequencing. The localization of aladin to the nuclear pore was assessed in cells expressing the patient variant.ResultsFunctional testing of the maternally inherited variant, p.(Arg270Pro), demonstrated decreased localization of aladin to the nuclear pore in cells expressing the variant, indicating a deleterious effect. Follow‐up testing in the proband's affected sister revealed that she also inherited the biallelic AAAS variants.ConclusionsReview of the patient's clinical, pathological, and genetic findings resulted in a diagnosis of Triple A syndrome.
Efficacy and safety of endoscopic ultrasound-guided gastrojejunostomy in patients with malignant gastric outlet obstruction and ascites
Mahmoud, Tala , Law, Ryan , Jaruvongvanich, Veeravich , Ghazi, Rabih , Abusaleh, Rami , Levy, Michael J. , Truty, Mark J. , Law, Ryan J, Storm, Andrew C. , Vargas, Eric J. , Bazerbachi, Fateh , Levy, Michael J. , Chandrasekhara, Vinay , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy International Open | May 13, 2022 | Volume: 10 | Issue: 05 | Pages: E670-E678

10.1055/a-1797-9318 | PMID 35571468 Get It

Abstract Background and study aims Endoscopic ultrasound-guided gastrojejunostomy (EUS-GJ) is an endoscopic procedure for treating gastric outlet obstruction (GOO). Limited data exist regarding the safety and efficacy of EUS-GJ in patients with malignant GOO with ascites. Thus, we aimed to study the outcomes and safety of EUS-GJ in GOO patients with vs. without ascites. Patients and methods This is a retrospective cohort study of patients with malignant GOO who underwent successful EUS-GJ at a tertiary care academic center. Primary outcomes included the efficacy and safety of EUS-GJ. Secondary outcomes included 30-day readmission, reintervention, and survival utilizing Kaplan-Meier analysis. Results A total of 55 patients (mean age of 67.0 ± 11.3 years, 40.0 % female) who underwent EUS-GJ, of whom 24 had ascites (small in 22, large in 2) were included. Clinical success was achieved in 91.7 % and 93.5 % (P = 1.00) of patients with and without ascites, respectively. A higher rate of adverse events (AEs) was noted in patients with ascites but this was not statistically significant (37.5 % vs. 19.4 %, P = 0.13). Four patients in the ascites group (16.6 %) developed clinical evidence of peritonitis or sepsis post-EUS-GJ. Eight patients with ascites developed worsening ascites within a month of EUS-GJ. In contrast, only one patient without ascites developed evidence of new ascites. The median survival of patients was not significantly different between the two groups (patients with ascites: 129 days vs. patients without ascites: 180 days, (P = 0.12). Conclusions The efficacy EUS-GJ in the presence of ascites is promising; however, the safety profile remains concerning given the high rate of AEs, specifically peritonitis and sepsis.
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
Alwan, Laura, Bachiashvili, Kimo, Baird, John H. , Cool, Rita, Dinner, Shira, Gojo, Ivana , Hicks, Ashley, Kidwai, Wajih Zaheer, Kloth, Dwight D. , Kraut, Eric H., Mahajan, Anjlee , Miller, Ryan, Nachar, Victoria , Patel, Shiven B. , Perez, Lia, Poust, Adam, Riaz, Fauzia , Rosovsky, Rachel , Simon, Shayna, Vasu, Sumithira , Wadleigh, Martha , Westbrook, Kelly , Westervelt, Peter, Berardi, Ryan A., Pluchino, Lenora A. , Griffiths, Elizabeth A. , Roy, Vivek , Geyer, Mark Blaine , Glaspy, John A. , Kallam, Avyakta , Landsburg, Daniel J. , Lyman, Gary H , Patel, Seema V. , Rugo, Hope S. , Simon, Shayna

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 11, 2022 | Volume: 20 | Issue: 5 | Pages: 436-442

10.6004/jnccn.2022.0026 | PMID 35545171 Get It

The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.
Heterozygous variants in PRPF8 are associated with neurodevelopmental disorders
O’Grady, Lauren , Vergano, Samantha A. Schrier , Hoffman, Trevor L. , Sarco, Dean, Cherny, Sara , Bryant, Emily , Schultz‐Rogers, Laura , Sacharow, Stephanie , Immken, LaDonna, Holder, Susan, Blackwell, Rebecca R., Buchanan, Catherine A., Yusupov, Roman, Lecoquierre, François , Guerrot, Anne‐Marie , Rodan, Lance H. , Vries, Bert B.A. de , Kamsteeg, Erik Jan, Palomares‐Bralo, María , Brown, Natasha J. , Klee, Eric W. , Babovic‐Vuksanovic, Dusica , Rhodes, Lindsay, Person, Richard, Begtrup, Amber, Keller‐Ramey, Jennifer, Santiago‐Sim, Teresa, Schnur, Rhonda E. , Gold, Nina B. , Schrier Vergano, Samantha , Lecoquierre, Francois , Rodan, Lance , de Vries, Bert B A , Santos Simarro, Fernando , Palomares-Bralo, Maria , Babovic-Vuksanovic, Dusica, Sweetser, David A , Chung, Wendy K. , Pais, Lynn , Ferrer, Alejandro , Begtrup, Amber Hogart

Mayo Clinic

American Journal of Medical Genetics Part A | May 11, 2022 | Volume: 188 | Issue: 9 | Pages: 2750-2759

10.1002/ajmg.a.62772 | PMID 35543142 Get It

Abstract The pre‐mRNA‐processing factor 8, encoded by PRPF8, is a scaffolding component of a spliceosome complex involved in the removal of introns from mRNA precursors. Previously, heterozygous pathogenic variants in PRPF8 have been associated with autosomal dominant retinitis pigmentosa. More recently, PRPF8 was suggested as a candidate gene for autism spectrum disorder due to the enrichment of sequence variants in this gene in individuals with neurodevelopmental disorders. We report 14 individuals with various forms of neurodevelopmental conditions, found to have heterozygous, predominantly de novo, missense, and loss‐of‐function variants in PRPF8 . These individuals have clinical features that may represent a new neurodevelopmental syndrome.
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions
Eastham, James A., Auffenberg, Gregory B. , Barocas, Daniel A. , Crispino, Tony, Davis, John W. , Eggener, Scott E. , Horwitz, Eric M. , Kirkby, Erin, Lin, Daniel W. , McBride, Sean M. , Rodrigues, George , Wong, William W. , Boorjian, Stephen A. , Chou, Roger , Kane, Christopher J. , Morgans, Alicia K. , Pierorazio, Phillip

Mayo Clinic

Journal of Urology | May 10, 2022 | Volume: 208 | Issue: 1 | Pages: 26-33

10.1097/ju.0000000000002759 | PMID 35536141 Get It

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up
Eastham, James A., Auffenberg, Gregory B. , Barocas, Daniel A. , Crispino, Tony, Davis, John W. , Eggener, Scott E. , Horwitz, Eric M. , Kirkby, Erin, Lin, Daniel W. , McBride, Sean M. , Rodrigues, George , Wong, William W. , Boorjian, Stephen A. , Chou, Roger , Kane, Christopher J. , Morgans, Alicia K. , Pierorazio, Phillip

Mayo Clinic

Journal of Urology | May 10, 2022 | Volume: 208 | Issue: 1 | Pages: 19-25

10.1097/ju.0000000000002758 | PMID 35536148 Get It

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management
Eastham, James A., Auffenberg, Gregory B. , Barocas, Daniel A. , Crispino, Tony, Davis, John W. , Eggener, Scott E. , Horwitz, Eric M. , Kirkby, Erin, Lin, Daniel W. , McBride, Sean M. , Rodrigues, George , Wong, William W. , Boorjian, Stephen A. , Chou, Roger , Kane, Christopher J. , Morgans, Alicia K. , Pierorazio, Phillip

Mayo Clinic

Journal of Urology | May 10, 2022 | Volume: 208 | Issue: 1 | Pages: 10-18

10.1097/ju.0000000000002757 | PMID 35536144 Get It